Loading clinical trials...

GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077) | Clinical Trials | Clareo Health

TERMINATED

GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)

Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol

NCT01355003•Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

This study will collect safety information on the use of GARDASIL™ in the Philippines.

Eligibility

Age

9 - 46 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Received GARDASIL™

Key Dates

Start Date

February 1, 2008

Primary Completion Date

June 1, 2010

Completion Date

June 1, 2010

Last Updated

August 13, 2015

Enrollment

1,080

ACTUAL participants

Conditions

Papillomavirus Infections

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689

Papillomavirus Infections

View study

COMPLETEDNA

Intervention for Human Papillomavirus Vaccine Acceptance in Mexican Mothers

NCT06854354

Papillomavirus InfectionsPapillomavirus Vaccines

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 13, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

TERMINATED

PHASE1/PHASE2